12% Weight Loss, Zero Injections
Since April, patients have been asking a version of the same question: now that there's a GLP-1 pill, do they still need the injection? It's a reasonable thing to wonder — but "pill instead of shot" isn't the same question as "as effective as" or "easier to tolerate." The trial data answers those separately.
The short version
What orforglipron actually is
Orforglipron, sold as Foundayo, is a small-molecule GLP-1 receptor agonist — a pill, not a peptide injection. Eli Lilly won FDA approval for it on April 1, 2026, for adults with obesity, or who are overweight with a weight-related condition, for use alongside a reduced-calorie diet and increased physical activity. Its main practical advantage over the other oral GLP-1 already on the market (oral semaglutide) is that it can be taken any time of day, with or without food or water; oral semaglutide requires taking it on an empty stomach and waiting before eating or drinking.
What the trials showed
The approval was supported by the Phase 3 ATTAIN program, which enrolled more than 4,500 adults with obesity or who were overweight across two 72-week, placebo-controlled global trials. Among participants who stayed on the highest dose, average weight loss was 12.4% (about 27 pounds) versus 0.9% with placebo; across all treated participants regardless of adherence, average weight loss was 11.1% versus 2.1% with placebo. Treatment was also linked to improvements in waist circumference, blood pressure, and lipids (non-HDL cholesterol and triglycerides).
Safety
Side effects aren't eliminated by the pill format. The most common adverse effects in trials were nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, and hair loss, with GI symptoms worst during the initial dose-escalation period and tending to ease afterward — the same pattern seen with injectable GLP-1s. Like other GLP-1 receptor agonists, orforglipron carries a boxed warning for potential thyroid C-cell tumors (including medullary thyroid carcinoma) and should not be used by anyone with a personal or family history of MTC or multiple endocrine neoplasia type 2. It shouldn't be combined with other GLP-1 receptor agonists.
Company leadership has acknowledged the pill doesn't match injectable GLP-1s on raw efficacy — Lilly's CEO has been direct that Zepbound produces more weight loss — but argues the pill still has a place for patients who want something less invasive than a weekly injection and cold-chain storage.
Where the pill actually helps
No needles, no cold-chain storage or injection training, and no pharmacy compounding concerns tied to injectable shortages. For people who are needle-averse or whose access to injectable GLP-1s has been inconsistent, that convenience is real. It isn't automatically cheaper or better covered by insurance — coverage varies by plan and is still evolving, though Lilly has published savings-card and self-pay pricing.
Bottom line
Foundayo is a legitimate, FDA-approved advance in how a GLP-1 can be delivered, with real efficacy data behind it — just generally somewhat less weight loss on paper than the highest-dose injectables, and comparable GI side effects. Whether a pill or an injection makes more sense depends on your history, tolerance, and goals, which is worth a real conversation with a provider rather than picking based on delivery method alone.
Sources: Eli Lilly investor relations (FDA approval announcement, April 2026); AJMC coverage of the ATTAIN Phase 3 program; Pharmacy Times, RxList, and NiceRx clinical prescribing/side-effect summaries.